PhoenixBio Co., Ltd. (6190.T)
JPY 341.0
(4.28%)
JPY 341.0
(4.28%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.18 Billion JPY | 12.98% |
| 2022 | 1.04 Billion JPY | 17.04% |
| 2021 | 895.4 Million JPY | 3.51% |
| 2020 | 865.02 Million JPY | -32.47% |
| 2019 | 1.28 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 330 Million JPY | 1.3% |
| 2023 Q2 | 304.43 Million JPY | 12.19% |
| 2023 Q4 | 325.76 Million JPY | 15.35% |
| 2023 Q3 | 282.42 Million JPY | -7.23% |
| 2023 FY | 1.18 Billion JPY | 12.98% |
| 2023 Q1 | 271.36 Million JPY | -1.99% |
| 2022 Q2 | 266.62 Million JPY | 0.0% |
| 2022 FY | 1.04 Billion JPY | 17.04% |
| 2022 Q4 | 276.88 Million JPY | 3.95% |
| 2022 Q3 | 266.36 Million JPY | -0.1% |
| 2021 FY | 895.4 Million JPY | 3.51% |
| 2020 FY | 865.02 Million JPY | -32.47% |
| 2019 FY | 1.28 Billion JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 1.28 Billion JPY | 7.823% |
| PRISM BioLab Co.,LTD | 576.81 Million JPY | -105.263% |
| GNI Group Ltd. | 9.32 Billion JPY | 87.299% |
| Linical Co., Ltd. | 2.7 Billion JPY | 56.233% |
| Trans Genic Inc. | 2.15 Billion JPY | 45.181% |
| MEDINET Co., Ltd. | 1.49 Billion JPY | 20.599% |
| Soiken Holdings Inc. | 3.07 Billion JPY | 61.447% |
| Cytori Cell Research Institute, Inc. | 1.85 Billion JPY | 36.241% |
| AnGes, Inc. | 8.9 Billion JPY | 86.7% |
| OncoTherapy Science, Inc. | 943.08 Million JPY | -25.545% |
| Nxera Pharma Co., Ltd. | 19.19 Billion JPY | 93.83% |
| Immuno-Biological Laboratories Co., Ltd. | 412.99 Million JPY | -186.687% |
| NanoCarrier Co., Ltd. | 975.37 Million JPY | -21.389% |
| Carna Biosciences, Inc. | 2.56 Billion JPY | 53.887% |
| CanBas Co., Ltd. | 278 Million JPY | -325.896% |
| D. Western Therapeutics Institute, Inc. | 1.14 Billion JPY | -3.719% |
| RaQualia Pharma Inc. | 1.81 Billion JPY | 34.872% |
| Chiome Bioscience Inc. | 1.6 Billion JPY | 26.174% |
| Kidswell Bio Corporation | 2.37 Billion JPY | 50.128% |
| PeptiDream Inc. | 9.68 Billion JPY | 87.778% |
| Oncolys BioPharma Inc. | 1.96 Billion JPY | 39.611% |
| Ribomic Inc. | 1.1 Billion JPY | -7.081% |
| SanBio Company Limited | 4.53 Billion JPY | 73.915% |
| Healios K.K. | 3.48 Billion JPY | 66.046% |
| BrightPath Biotherapeutics Co., Ltd. | 1.15 Billion JPY | -2.533% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 1.33 Billion JPY | 11.276% |
| Delta-Fly Pharma, Inc. | 1.4 Billion JPY | 15.638% |
| StemRIM | 2.07 Billion JPY | 42.968% |
| CellSource Co., Ltd. | 1.96 Billion JPY | 39.7% |
| FunPep Company Limited | 313.82 Million JPY | -277.282% |
| Kringle Pharma, Inc. | 958.01 Million JPY | -23.588% |
| Stella Pharma Corporation | 963.98 Million JPY | -22.822% |
| TMS Co., Ltd. | 943.25 Million JPY | -25.522% |
| Noile-Immune Biotech Inc. | 1.08 Billion JPY | -8.628% |
| Cuorips Inc. | 598.11 Million JPY | -97.953% |
| K Pharma,Inc. | 543.94 Million JPY | -117.668% |
| Takara Bio Inc. | 23.9 Billion JPY | 95.047% |
| ReproCELL Incorporated | 1.51 Billion JPY | 21.798% |
| StemCell Institute Inc. | 1.16 Billion JPY | -1.882% |
| Japan Tissue Engineering Co., Ltd. | 1.52 Billion JPY | 22.222% |
| CellSeed Inc. | 804.93 Million JPY | -47.092% |